REGIONAL EXPERIENCE WITH VIROLOGICAL CERVICAL SCREENING IN THE SVERDLOVSK REGION


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To evaluate the clinical sensitivity and specificity of a care system for human papillomavirus (HPV) for the identification of its DNA in an organized screening program versus conventional cytology in the remote areas of the Sverdlovsk Region. Subjects and methods. A total of 857 women underwent cervical screening by the hybrid capture HPV DNA test using the careHPV testing system, with a parallel cytological examination by the conventional method, followed by a colposcopic, pathomorphological study in patients with a positive HPV test and/or altered cytological patterns. Results. A high-titer high-risk HPV (hr-HPV) positive test using the careHPV diagnostic system was seen in 84 patients: 35 (41.67%) hrHPV-positive women were found to have cervical precancer and cancer, while 16 (2.07%) hrHPV-negative patients with the visually altered cervix had cervical intraepithelial neoplasia 1 (CIN 1). Virological screening was ascertained to have a signif icantly higher sensitivity in high-grade CIN and cervical cancer (CC), which demonstrates the feasibility of using this method during CC screening in the remote areas. Conclusion. This investigation and calculations of screening methods demonstrated that the hybrid capture test using the careHPV diagnostic system versus conventional cytology had a significantly higher sensitivity in identifying high-grade CIN and CC, but cytology had a higher specificity.

Full Text

Restricted Access

About the authors

Irina N. Kononova

Research Institute of Maternal and Infant Care, Ministry of Health of the Russian Federation

Email: irkonmed@mail.ru
MD, associate professor, acting Leading Researcher, Head of the Training Center 620028 Russia, Yekaterinburg, ul. Repin, d.1

Nadezhda V. Bashmakova

Research Institute of Maternal and Infant Care, Ministry of Health of the Russian Federation

Email: dr@niiomm.ru
MD, professor, chief obstetrician-gynecologist of the Ural Federal District, chief researcher 620028 Russia, Yekaterinburg, ul. Repin, d.1

Oksana E. Gaeva

Research Institute of Maternal and Infant Care, Ministry of Health of the Russian Federation

Email: eletty@mail.ru
graduate student obstetrician-gynecologist 620028 Russia, Yekaterinburg, ul. Repin, d.1

Tamara V. Krest'yaninova

Women's Health Clinic, P.D. Borodin Central Town Hospital

doctor obstetrician-gynecologist, head 624090 Russia, Sverdlovsk region, Verkhnyaya Pyshma, ul. Tchaikovsky, d. 32

References

  1. Tang Y, Zheng L, Yang S., Li B., Su H., Zhang L.P. Epidemiology and genotype distribution of human papillomavirus (HPV) in Southwest China: a crosssectional five years study in non-vaccinated women. Virol. J. 2017; 14(1): 84.
  2. Обоскалова Т.А., Кононова И.Н., Севостьянова О.Ю., Берзин С.А. Эпидемиологические особенности рака шейки матки у жительниц крупного промышленного города. Уральский медицинский журнал. 2014; 4: 69-72.
  3. WHO/ICO Information Centre on HPV and Cancer. Russian Federation: Human Papillomavirus and Related Cancers, Fact Sheet 2016. Available at: http//www.hpvcentre.net
  4. Аксель Е.М., Виноградова Н.Н. Статистика злокачественных новообразований женских репродуктивных органов. Онкогинекология. 2018; 3: 64-9.
  5. Zur Hausen H. Are human papillomavirus infections not necessary or sufficient causal factors for invasive cancer of the cervix? Int. J. Cancer. 1995; 63(2): 315-6.
  6. Heard I., Etienney I., Potard V. et al. Factors associated with prevalent anal cancer precursors in asymptomatic HIV-infected women. In: Abstracts 15th World congress for cervical pathology and colposcopy. 26 May-30 May London 2014: 40-1.
  7. Macbalek D.A., Poynten M., Jin F., Fairley C.K., Farnsworth A., Garland S.M. et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol. 2012; 13(5): 487-500.
  8. Castle P.E., Qiao Y.L., Zhao F.H., Chen W., Valdez M, Zhang X. et al. Clinical determinants of a positive visual inspection after treatment with acetic acid for cervical cancer screening. BJOG. 2014; 12(6): 739-46.
  9. Кононова И.Н., Ворошилина Е.С. Особенности местного иммунитета при цервикальных интраэпителиальных неоплазиях, ассоциированных с папилломавирусной инфекцией. Российский иммунологический журнал. 2014; 8(3): 809-11.
  10. Fontecha N., Arrese E., Andia D., Cisterna R., Basaras M. RNA extraction method is crucial for human papillomavirus E6/E7 oncogenes detection. Virol. J. 2017; 14(1): 50.
  11. Кононова И.Н. Эпидемиология папилломавирусной инфекции в крупном промышленном городе. Охрана материнства и детства (Витебск). 2015; 1: 9-13.
  12. Рекомендации ВОЗ по выявлению и лечению предраковых поражений для профилактики рака шейки матки. М.; 2013.
  13. Blatt A.J., Kennedy R., Luff R., Austin R.M., Rabin D.S. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 2015; 123(5): 282-8.
  14. Keegan H., Mc Inerney J., Pilkington L., Gronn P., Silva I., Karlsen F. et al. Comparison of HPV detection technologies: Hybrid Capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/ E7 mRNA positive specimens. J. Virol Methods. 2009; 155(1): 61-6.
  15. Monteiro C., Rebelo T., Figueiredo Dias M. New molecular markers in HPV infection risk stratification: systematic review. In: Abstracts 18th International multidisciplinary HPV congress EUROGIN. Lisbon, Portugal, December 2018.
  16. Varl J., Ivanus U., Jerman T., Nolde N., Prevodnik V.K. Clinical significance of HC2 Test results in grej zone range used in Slovenian cancer screening program zora. In: Abstracts 18th International multidisciplinary HPV congress EUROGIN. Lisbon, Portugal, December 2018.
  17. Meijer C.J., Berkhof J., Castle P.E., Hesselink A.T., Franco E.L., Ronco G. et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int. J. Cancer. 2009; 124(3): 516-20.
  18. Carozzi F.M., Del Mistro.A., Confortini.M., Sani.C., Puliti.D., Trevisan.R. еt al. Reproducibility of HPV DNA testing by hybrid capture 2 in a screening setting. Am. J. Clin. Pathol. 2005; 124(5): 716-21.
  19. Флетчер Р., Флетчер С., Вагнер Э. Клиническая эпидемиология. Основы доказательной медицины. М.: Медиа Сфера; 1998. 352 с.
  20. Wright T., Zhang G., Behrens C.M. Screening with prejudice; how knowledge of patients HPV status impacts the performance of cervical cytology in the ATHENA trial. In: Abstracts 15th World congress for cervical pathology and colposcopy. 26 May-30 May London 2014: 56-7.
  21. Camara Hawa, Nosi Somu, Guy Rebecca, Lafferty Lise, Vallely Andrew, Kelly-Hanku Angela. Apceptability of self-collected POC HPV-based testing: a qualitative meta-synthesis. In: Abstracts 18th International multidisciplinary HPV congress EUROGIN. Lisbon, Portugal, December 2018.
  22. Coutinho F., Coutinho L., Oliveira J., Ramos V., Carvalho MJ., Caramero O. et al. Atypycal glandular cells on pap testing and its correlations to HPV. Abstracts 18th International multidisciplinary HPV congress EUROGIN. Lisbon, Portugal, December 2018.
  23. Обоскалова Т.А., Кононова И.Н., Ворошилина Е.С. Иммунокоррекция кавитированными ультразвуком растворами в комплексном лечении цервикальных интраэпителиальных неоплазий, ассоциированных с папил-ломавирусной инфекцией. Уральский медицинский журнал. 2013; 4: 46-51.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies